SCM
JSPR icon

Stonepine Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Stonepine Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,200
Closed -$48.1K – 78
2025
Q3 		$48.1K Buy
+20,200
New +$61.3K 0.04% 58

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Stonepine Capital Management's JSPR Position: Q4 2025 in Review

Stonepine Capital Management sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 20,200 shares — an estimated $48.1K sold.

Stonepine Capital Management first reported a position in JSPR in Q3 2025 and held it in 1 quarter. The position peaked at $48.1K in Q3 2025. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Stonepine Capital Management reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 20,200 Jasper Therapeutics shares in Q4 2025, an estimated $48.1K.
  • Stonepine Capital Management first reported a position in Jasper Therapeutics in Q3 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Jasper Therapeutics position peaked at $48.1K in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.